摘要
目的研究小儿咳嗽变异型哮喘应用盂鲁司特联合氯雷他定治疗时血清干扰素1（IFN-γ）和白细胞介素4（IL-4）水平的变化。方法收集46例确诊为咳嗽变异型哮喘患儿，予孟鲁司特联合氯雷他定治疗8周，比较治疗前后血清IFN-γ和IL-4水平的变化。结果46例患儿治疗前后血清IFN-γ水平分别为（59．94±9．43）、（39．94±9．07）ng/L，IL-4水平分别为（48．78±22．23）、（60．78±16．48）ng，L。治疗前后两种细胞因子水平比较差异均有统计学意义（P〈0．05）。结论孟鲁司特联合氯雷他定治疗小儿咳嗽变异型哮喘，能够调节IFN-γ、IL-4水平失衡，值得进一步研究。
Objective To study the change of serum interferon-γ/（IFN-γ ） and interleukin-4（IL-4） level in children suffered from cough variant asthma after montelukast combined with ]oratadine therapy. Methods Forty-six patients of children cough variant asthma were recruited and accepted montelukast combined with loratadine therapy for 8 weeks. The changes of serum IFN-γ and IL-4 before and after therapy were compared. Results Compared with before therapy,the level of serum IFN-γwas decreased [ （59.94 ± 9.43 ） ng/L vs. （39.94 ± 9.07 ） ng/L ] and IL-4 was increased[ （48.78 ± 22.23 ） ng/L vs. （60.78 ± 16.48） ng/L] after therapy, there were significant differences （P 〈0.05）. Conclusion Montelukast combined with ]oratadine in the treatment of children cough variant asthma can improve the balance of IFN- γ/IL-4, which deserve further study.
出处
《中国医师进修杂志》
2012年第10期13-14,共2页
Chinese Journal of Postgraduates of Medicine
作者简介
通信作者：韩雪梅，Email：hanxuemeiml@163．com
